Cue Biopharma
Targeting functional cures for immunological disorders
Precision immuno-engineered therapies designed to address significant unmet medical needs with the goal to transform patients’ lives across allergic and autoimmune diseases.
About Us
We are a clinical-stage biopharmaceutical company focused on advancing a robust portfolio of therapies aimed at enabling functional cures across allergic and autoimmune diseases.
Our Pipeline
Our Lead Programs
CUE-221
Novel anti-IgE program with a unique dual-mechanism-of-action, in Phase 2 for allergic diseases.
Allergy
Phase 2
CUE-401
Bifunctional IL-2 and TGF-β designed to restore immune balance utilizing Treg-mediated tolerance, advancing into Phase 1 development.
Autoimmune & Inflammation
Phase 1-Ready
For Investors
Differentiated Science with Strong Growth Potential.
Cue Biopharma is a clinical-stage biopharmaceutical company targeting the development of transformative therapies for immunological disorders with high unmet need. We are led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates. We invite investors to follow our progress.
News & Press
Cue in the News
New Leadership Addition
Dominic Borie, M.D., Ph.D., Joins Cue as
Chief Medical Officer and Head of Research and Development
First Quarter 2026
First Quarter 2026 Financial Results and Recent Strategic Developments